Document is current
Any future updates will be listed below
-
Authors
Robledo-Montaña, Javier https://orcid.org/0000-0002-6975-3452
Díaz-García, César https://orcid.org/0009-0006-2019-8570
Martínez, María https://orcid.org/0000-0002-6308-4243
Ambrosio, Nagore https://orcid.org/0000-0001-9837-5393
Montero, Eduardo https://orcid.org/0000-0003-2525-8529
Marín, María José https://orcid.org/0000-0003-0206-4756
Virto, Leire https://orcid.org/0000-0002-3376-5232
Muñoz-López, Marina https://orcid.org/0000-0003-4817-9639
Herrera, David https://orcid.org/0000-0002-5554-2777
Sanz, Mariano https://orcid.org/0000-0002-6293-5755
Leza, Juan Carlos https://orcid.org/0000-0002-9901-0094
García-Bueno, Borja https://orcid.org/0000-0001-7320-1530
Figuero, Elena https://orcid.org/0000-0002-3129-1416
Martín-Hernández, David https://orcid.org/0000-0003-0195-2604
-
Funding
Funding for this research was provided by:
MINECO-FEDER Funds (PID2019-109033RB-100, PID2019-109033RB-100)
CIBERSAM/ISCIII
Santander-University Complutense of Madrid Projects (PR41/17–20979)
- License Information
-
More Information
Article History
Received: 7 March 2024
Accepted: 29 August 2024
First Online: 8 September 2024
Declarations
:
: This study was designed according to the modified ARRIVE guidelines 2.0 for preclinical in vivo research [] and following Spanish and European Union regulations (European Communities Council Directive 86/609/EEC). The in vivo experimental part of the study was carried out in the Experimental Animal Center of the Complutense University of Madrid after its protocol was approved by the regional authorities (PROEX 087/18) and the Ethical Committee of Animal Experimentation.
: Not applicable.
: The authors declare no competing interests.
